Denmark Cancer Diagnostics Market Size & Outlook
Denmark cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Denmark cancer diagnostics market highlights
- The Denmark cancer diagnostics market generated a revenue of USD 838.7 million in 2023 and is expected to reach USD 1,123.5 million by 2030.
- The Denmark market is expected to grow at a CAGR of 4.3% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 838.7 million |
| Market revenue in 2030 | USD 1,123.5 million |
| Growth rate | 4.3% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Denmark accounted for 0.8% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 59.97% in 2023. Horizon Databook has segmented the Denmark cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
The Denmark market is driven by the presence of a well-established healthcare infrastructure, high disease burden, and a growing demand for noninvasive diagnostic tests. According to World Cancer Research Fund International, Denmark has the highest cancer prevalence among women and men combined in 2022, prompting the government to boost diagnosis & treatment rates.
For instance, in September 2022, Delfi Diagnostics, a leader in liquid biopsy, was selected as the designated partner for conducting liquid lung cancer biopsies in the EU’s multinational lung cancer screening trial, 4-IN-THE-LUNG-RUN (4ITLR).
The Danish Ministry of Health defines the framework for the national healthcare system. The Danish Medicines Agency (DKMA), a government organization regulated under the Ministry of Health, is responsible for monitoring laboratory tests, including diagnostic tests.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Denmark cancer diagnostics market size, by product, 2018-2030 (US$M)
Denmark Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
